GSK fears Synflorix may be no match for Prevnar in the US
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlinehas said that it may not apply to market its new 10-valent pneumococcal vaccine Synflorix in the US because of the tough competition it would meet from Wyeth's blockbuster seven-valent vaccine Prevnar.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.